Cloning and expression of murine IL-12 - PubMed (original) (raw)
. 1992 Jun 1;148(11):3433-40.
Affiliations
- PMID: 1350290
Cloning and expression of murine IL-12
D S Schoenhaut et al. J Immunol. 1992.
Abstract
Human IL-12 (NK cell stimulatory factor, cytotoxic lymphocyte maturation factor) is a heterodimeric cytokine that can act as a growth factor for activated human T and NK cells, enhance the lytic activity of human NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting human PBMC. Because in our hands, human IL-12 did not elicit similar responses in murine lymphocytes, we have cloned and expressed the murine IL-12 subunit cDNA in order to obtain recombinant protein for murine studies. Comparison of the predicted amino acid sequences of the murine subunits with their human counterparts revealed that the p40 subunits are more highly conserved than the p35 subunits (70% vs 60% identity, respectively). The sizes of the p35 and p40 subunit mRNA were estimated to be 1.5 kb and 2.6 kb, respectively. RNA blot analysis showed that p35 mRNA was expressed in lymphoid tissues (spleen, thymus) and nonlymphoid tissues (lung, brain), whereas p40 mRNA expression was only detected in lymphoid cells. Incubation of splenocytes with pokeweed mitogen did not significantly affect p35 mRNA levels, however, it resulted in a decrease of p40 mRNA. Coexpression of the murine p35 and p40 cDNA clones in COS cells resulted in the secretion of IL-12, which was active in human and mouse T cell proliferation, murine NK cell activation, and murine IFN-gamma induction assays. Transfection of each subunit cDNA alone did not result in measurable secreted IL-12 activity. A hybrid heterodimer consisting of murine p35 and human p40 subunits retained bioactivity on murine cells; however, the combination of human p35 and murine p40 was completely inactive on murine cells. These results indicate that the observed inability of human IL-12 to act on murine cells is largely determined by the p35 subunit.
Similar articles
- Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells.
Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM, et al. Wolf SF, et al. J Immunol. 1991 May 1;146(9):3074-81. J Immunol. 1991. PMID: 1673147 - Ovine interleukin 12 has biological activity on ovine and human activated peripheral blood mononuclear cells.
Swinburne SJ, Russ GR, Krishnan R. Swinburne SJ, et al. Cytokine. 2000 Oct;12(10):1546-52. doi: 10.1006/cyto.2000.0755. Cytokine. 2000. PMID: 11023671 - Differential expression of mRNA encoding interleukin-12 p35 and p40 subunits in situ.
Bette M, Jin SC, Germann T, Schäfer MK, Weihe E, Rüde E, Fleischer B. Bette M, et al. Eur J Immunol. 1994 Oct;24(10):2435-40. doi: 10.1002/eji.1830241026. Eur J Immunol. 1994. PMID: 7925572 - Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H, Lotze MT. Tahara H, et al. Gene Ther. 1995 Mar;2(2):96-106. Gene Ther. 1995. PMID: 7719935 Review. - The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes.
Airoldi I, Guglielmino R, Carra G, Corcione A, Gerosa F, Taborelli G, Trinchieri G, Pistoia V. Airoldi I, et al. Haematologica. 2002 Apr;87(4):434-42. Haematologica. 2002. PMID: 11940489 Review.
Cited by
- Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.
Kurokawa C, Agrawal S, Mitra A, Galvani E, Burke S, Varshine A, Rothstein R, Schifferli K, Monks NR, Foloppe J, Silvestre N, Quemeneur E, Demeusoit C, Kleinpeter P, Sapra P, Barrett C, Hammond SA, Kelly EJ, Laliberte J, Durham NM, Oberst M, Broggi MAS. Kurokawa C, et al. Mol Ther Oncol. 2024 Jan 10;32(1):200758. doi: 10.1016/j.omton.2023.200758. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596304 Free PMC article. - XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.
Patel E, Malkova NV, Crowe D, Pederzoli-Ribeil M, Fantini D, Fanny M, Madala HR, Jenkins KA, Yerov O, Greene J, Guzman W, O'Toole C, Taylor J, O'Donnell RK, Johnson P, Lanter BB, Ames B, Chen J, Vu S, Wu HJ, Cantin S, McLaughlin M, Hsiao YS, Tomar DS, Rozenfeld R, Thiruneelakantapillai L, O'Hagan RC, Nicholson B, O'Neil J, Bialucha CU. Patel E, et al. Mol Cancer Ther. 2024 Apr 2;23(4):421-435. doi: 10.1158/1535-7163.MCT-23-0336. Mol Cancer Ther. 2024. PMID: 38030380 Free PMC article. - Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL.
Zhou W, Miao J, Cheng Z, Wang Z, Wang J, Guo H, Wang P, Lu S, Si L, Zhang Z, Dunmall LC, Liu Y, Lemoine NR, Wang Y. Zhou W, et al. Mol Ther Oncolytics. 2023 Aug 18;30:216-226. doi: 10.1016/j.omto.2023.08.009. eCollection 2023 Sep 21. Mol Ther Oncolytics. 2023. PMID: 37663131 Free PMC article. - Human IL-35 Inhibits the Bioactivity of IL-12 and Its Interaction with IL-12Rβ2.
Mahfooz NS, Merling MR, Claeys TA, Dowling JW, Forero A, Robinson RT. Mahfooz NS, et al. Immunohorizons. 2023 Jun 1;7(6):431-441. doi: 10.4049/immunohorizons.2300039. Immunohorizons. 2023. PMID: 37289499 Free PMC article. - Construction of VSVΔ51M oncolytic virus expressing human interleukin-12.
Abdulal RH, Malki JS, Ghazal E, Alsaieedi AA, Almahboub SA, Khan MY, Alsulaiman RM, Ghaith MM, Abujamel TS, Ganash M, Mahmoud AB, Alkayyal AA, Hashem AM. Abdulal RH, et al. Front Mol Biosci. 2023 May 15;10:1190669. doi: 10.3389/fmolb.2023.1190669. eCollection 2023. Front Mol Biosci. 2023. PMID: 37255540 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials